clarithromycin
Commercial- Indications
- Helicobacter pylori infection
Company intelligence / Profile preview
Jun-Won Chung
Seongnam-si, Gyeonggi-do, South Koreapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CAIMI has published peer-reviewed research validating its artificial intelligence computer-aided detection system for early esophageal cancer using multi-institutional imaging data. The system demonstrated robust performance in clinical settings.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- DeviceSoftware (AI-based diagnostic tool)
- Industry
- Digital Health Medical Devices
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Academic collaborations with Gachon University and multiple medical institutions in Korea as part of multi-institutional studies
Beyond the preview
Go deeper on Jun-Won Chung.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jun-Won Chung.